Pan-αβ TCR-targeting VHHs enable orthogonal T cell activation with strong cytotoxicity and species cross-reactivity

Engineered TCR variants show >30,000-fold affinity gains, high specificity, and potent target cell killing

TfR1 antibody panel enables blood-brain barrier transport with strong internalization and brain accumulation

Minimal engineering resolves prevalent off-target binding in clinical antibodies

Engineered HC–LC interfaces direct correct chain pairing, enabling high-purity multispecific antibodies

Highly developable soluble T cell receptors (TCRs) with high target affinities discovered from large yeast libraries